Zealand Pharma
Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines for metabolic and gastrointestinal diseases. The company operates through research and clinical development segments dedicated to creating novel therapeutics addressing obesity, diabetes, and rare disorders. Its principal revenue drivers stem from milestone payments, research collaborations, and commercial license agreements established with major pharmaceutical partners, alongside future drug commercialization prospects. The firm maintains a significant international scale and a specialized market position within peptide drug discovery and metabolic healthcare innovation, collaborating with global industry leaders. By advancing proprietary therapeutic candidates through rigorous clinical trials, the enterprise addresses critical unmet medical needs. Zealand Pharma is officially headquartered in Søborg, Denmark, and its ordinary shares are publicly listed and traded on Nasdaq Copenhagen.
26 of the funds FundTelligence covers report a position in Zealand Pharma.
- Legal name
- Zealand Pharma AS
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 26
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding Zealand Pharma
- Nordnet Danmark Indeks — Nordnet · 0.89 % (full portfolio disclosed, October 2026)
- Nordea Danmark — Nordea Funds · 0.86 % (full portfolio disclosed, September 2026)
- Nordea Danske aktier fokus — Nordea Funds · 0.82 % (full portfolio disclosed, September 2026)
- Danske Invest Denmark Focus — Danske Invest · 0.64 % (full portfolio disclosed, September 2026)
- SEB Nordenfond — SEB · 0.54 % (full portfolio disclosed, June 2026)
- Alfred Berg Nordic Small Cap — Alfred Berg · 0.41 % (full portfolio disclosed, June 2026)
- BNP Nordic Small Cap — BNP Paribas · 0.36 % (full portfolio disclosed, June 2026)
- DNB Fund Nordic Small Cap — DNB · 0.35 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 26 funds holding it.